Skip to content
香港聯合腫瘤中心
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En
  • Cancer diagnosis
    • Physical examination
      • Male/Female physical examination plan
    • Endoscopic examination
    • X-ray
    • Ultrasound examination
    • Laboratory examination
    • Cytological examination
    • Pathological diagnosis
    • Positron emission tomography and computed tomography (PET/CT)
    • Magnetic resonance imaging (MRI)
    • Computed tomography (CT) scan
    • Genetic testing
  • Cancer treatment
    • Information for newly diagnosed patients
    • Surgery
    • Radiotherapy
    • Chemotherapy
      • Side Effect
      • Chemotherapy Instructions
      • cancer cell characteristics, and individual constitution.
    • Gene-directed targeted therapy
    • Targeted therapy
    • Hormone therapy
    • Immunotherapy
    • Hyperbaric oxygen therapy
      • Sudden hearing loss
      • Ischemic stroke / Cerebral stroke
      • Diabetic foot ulcers
      • Applications in oncology
  • Types of cancer
    • What is cancer
    • breast cancer
    • Lung cancer
      • Lung cancer articles and reports
    • colorectal cancer
    • liver cancer
    • stomach cancer
    • prostate cancer
    • thyroid cancer
    • brain cancer
    • nasopharyngeal cancer
    • cervical cancer
    • pancreatic cancer
    • Uterine body cancer
  • Cancer information
    • New cancer drugs
      • Lung cancer drugs
      • Breast cancer drugs
      • Bile duct cancer drugs
      • Liver cancer drugs
      • Bowel cancer drugs
      • Urothelial carcinoma drugs
      • Prostate cancer drugs
    • News report
    • Cancer information video
    • Medical lectures
    • Doctor Q&A
  • Clinical research
  • Contact us
    • Contact methods
    • Doctor Updates
    • Join us
  • 繁
  • En

Category: 子宮內膜癌

ELAHERE antibody-drug complex demonstrates breakthrough efficacy in gynecological cancers.

Antibody-drug conjugates show groundbreaking efficacy in gynecological cancers. The recently approved mirvetuximab soravtansine-gynx confirms the potential of antibody-drug conjugates (ADCs) in recurrent ovarian cancer.

立即閱讀
July 4, 2025 No Comments

Mivatuximab and solatumin have received routine approval for the treatment of FRα-positive platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Mirvetuximab soravtansine received regular approval for FRα-positive, platinum-resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. On March 22, 2024, the U.S. FDA officially approved mirvetuximab soravtansine.

立即閱讀
July 4, 2025 No Comments

ELAHERE, a newsletter on innovative treatments for gynecological cancers

Gynecological Cancer Innovative Treatment Research Update: The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting presented several research findings that will change clinical practice. Here is a summary of key advancements: Ovarian Cancer: MIRASOL final analysis confirmed [results].

立即閱讀
July 4, 2025 No Comments

Expert Opinion: Dr. Alan P. Venook discusses the CheckMate 8HW trial of Dostarlimab

Expert Opinion: Dr. Alan P. Venook discusses the CheckMate 8HW trial. Alan P. Venook, MD, is from the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco.

立即閱讀
July 4, 2025 No Comments

Application of Dostarlimab combination therapy in advanced endometrial cancer

Dostarlimab聯合治療方案在晚期子宮內膜癌中的應用 在2024年婦科腫瘤學會(SGO)年會上，RUBY/ENGOT-EN6/GOG3031/N

立即閱讀
July 4, 2025 No Comments

Immunotherapy combined with chemotherapy significantly improves survival in advanced/recurrent endometrial cancer: Important data from the RUBY and NRG-GY018 trials released. Dostarlimab

免疫聯合化療顯著改善晚期/復發性子宮內膜癌存活期：RUBY與NRG-GY018試驗重要數據公佈 在2024年SGO年會上公佈的RUBY和NRG-GY0

立即閱讀
July 4, 2025 No Comments

Expert Opinion: Dr. Gini F. Fleming Discusses a New Landscape in Immunotherapy for Endometrial Cancer: Dostarlimab

專家觀點：Gini F. Fleming博士談子宮內膜癌免疫治療新格局 在2024年SGO年會上，芝加哥大學婦科腫瘤醫學主任Gini F. Flemi

立即閱讀
July 4, 2025 1 Comment

NCCN Clinical Practice Guidelines in Oncology: Key Updates for 2024 - Dostarlimab

NCCN腫瘤學臨床實踐指南：2024年更新要點 美國國家綜合癌症網絡（NCCN®）於1996年首次發布《腫瘤學臨床實踐指南》（NCCN Guideli

立即閱讀
July 4, 2025 No Comments

The LEAP-001 study did not meet its primary endpoint, but Lenvatinib/Pembrolizumab still showed efficacy in a specific subgroup of endometrial cancer.

LEAP-001研究未達主要終點，但Lenvatinib/Pembrolizumab仍對特定子宮內膜癌亞組顯示療效 備受矚目的ENGOT-en9/LE

立即閱讀
July 4, 2025 No Comments

The FDA expands the indication for Dostarlimab-gxly in combination with chemotherapy for endometrial cancer.

FDA擴展Dostarlimab-gxly聯合化療用於子宮內膜癌的適應症 8月1日，美國食品及藥物管理局（FDA）批准dostarlimab-gxly

立即閱讀
July 4, 2025 No Comments
Page1 Page2
香港聯合腫瘤中心

The Hong Kong United Oncology Centre (HKUOC) provides cancer-related medical services such as cancer screening, cancer diagnosis and cancer treatment, including immunotherapy, chemotherapy, targeted drug therapy, radiation therapy, hormone therapy and palliative care.

Contact us

  • Address: Rooms 01-06, 20/F, 238 Nathan Road, Kowloon (MTR Jordan Station Exit E)
  • Phone: +852 2386 8002
  • WhatsApp：5518 2992
  • Fax: (852) 2386 8229
  • Macau: Enquiry@hkuoc.hk

Consultation time

Monday to Friday

9:00 am to 1:00 pm

2:00 p.m. to 6:00 p.m.

Saturday

9:00 am to 1:00 pm

Closed on Sundays and public holidays

Types of cancer

  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer
  • breast cancer
  • Lung cancer
  • colorectal cancer
  • liver cancer
  • stomach cancer
  • prostate cancer
  • thyroid cancer
  • brain cancer
  • nasopharyngeal cancer
  • pancreatic cancer
  • Uterine body cancer

Cancer treatment

  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy
  • Information for newly diagnosed patients
  • Surgery
  • Radiation therapy (electrotherapy)
  • Chemotherapy
  • Targeted therapy
  • Hormone therapy
  • Immunotherapy

phone

WhatsApp

Facebook